HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

After hitting a record high of HK$72.85/share in June, the share price of <a href="https://www.smartkarma.com/entities/microport-scientific-corp" target="_blank" data-smartkarma-citation="entities:4487:1" rel="noopener">Microport Scientific (853 HK) </a>has fallen continuously in the following months, down over 45% by the end of October 8, 2021. This insight mainly analyzed the 2021/1H performance, the business, the concerns and the outlook of MicroPort, including both the favorable and the unfavorable aspects.

After hitting a record high of HK$72.85/share in June, the share price of Microport Scientific (853 HK) has fallen continuously in the following months, down over 45% by the end of October 8, 2021. This insight mainly analyzed the 2021/1H performance, the business, the concerns and the outlook of MicroPort, including both the favorable and the unfavorable aspects.

Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects

Beijing Chunlizhengda Medical Instruments / Equity Bottom-Up

Beijing Chunlizhengda Medical Instruments (1858 HK)

Beijing Chunlizhengda Medical Instruments

Different from <a href="https://www.smartkarma.com/entities/ak-medical-holdings-limited" target="_blank" data-smartkarma-citation="entities:23669:1" rel="noopener">AK Medical Holdings Limited (1789 HK)</a> who was a big domestic winner in the national centralized procurement of artificial joints this month with the whole product lines successfully included in the medical insurance catalogue, <a href="https://www.smartkarma.com/entities/beijing-chunlizhengda-medical-instruments-co-ltd" target="_blank" data-smartkarma-citation="entities:7568:1" rel="noopener">Beijing Chunlizhengda Medical Instruments (1858 HK)</a> lost the bidding of its important knee joint prosthesis products in this centralized procurement. The Company's share price fell for two consecutive trading days by 17% on Sep.15 and 8.21% on Sep.16. This insight mainly analyzed the potential impact of losing the bidding, the concerns and the business outlook of Chunlizhengda.

Different from AK Medical Holdings Limited (1789 HK) who was a big domestic winner in the national centralized procurement of artificial joints this month with the whole product lines successfully included in the medical insurance catalogue, Beijing Chunlizhengda Medical Instruments (1858 HK) lost the bidding of its important knee joint prosthesis products in this centralized procurement. The Company's share price fell for two consecutive trading days by 17% on Sep.15 and 8.21% on Sep.16. This insight mainly analyzed the potential impact of losing the bidding, the concerns and the business outlook of Chunlizhengda.

Chunlizhengda Medical Instruments (1858.HK) - The Concerns and the Outlook After Losing the Bidding

AK Medical Holdings Limited / Equity Bottom-Up

On September 14, 2021, the results of the national centralized procurement of artificial joints was released. This is the second national centralized procurement on high-value consumables organized by the State after the coronary stents last year. <a href="https://www.smartkarma.com/entities/ak-medical-holdings-limited" target="_blank" data-smartkarma-citation="entities:23669:1" rel="noopener">AK Medical Holdings Limited (1789 HK)</a>, one of the leading companies in the field of joint implants, offered low prices in several rounds of bidding and its products were successfully included in the medical insurance catalogue. On that day, AK Medical’s share price increased over 20%. This insight mainly analyzed the industry characteristics, the impact of centralized procurement on AK Medical’s business and the outlook of the Company.

On September 14, 2021, the results of the national centralized procurement of artificial joints was released. This is the second national centralized procurement on high-value consumables organized by the State after the coronary stents last year. AK Medical Holdings Limited (1789 HK), one of the leading companies in the field of joint implants, offered low prices in several rounds of bidding and its products were successfully included in the medical insurance catalogue. On that day, AK Medical’s share price increased over 20%. This insight mainly analyzed the industry characteristics, the impact of centralized procurement on AK Medical’s business and the outlook of the Company.

AK Medical Holdings Limited (1789.HK) - A Safe Landing After the Centralized Procurement

<a href="https://www.smartkarma.com/entities/microport-scientific-corp" target="_blank" data-smartkarma-citation="entities:4487:1" rel="noopener">Microport Scientific (853 HK)</a> is an innovation-driven medical device platform with a diversified product portfolio covering cardiovascular, orthopedics, cardiac rhythm management (“CRM”), endovascular, neurovascular, heart valve, surgical robot and other business. The Company’s high valuation mainly comes from the outlook and embrace of new technologies and new fields. In order to ensure the sustainability of R&amp;D investment, retain talent and maintain growth momentum, subsidiaries were spun-off and then listed one by one when they became mature. Finally, the scope of MicroPort is also expanded, and then the focus can be put on incubating new companies. However, this “unique” pattern of development has also raised questions, especially when compared with <a href="https://www.smartkarma.com/entities/shenzhen-mindray-bio-medic-a" target="_blank" data-smartkarma-citation="entities:28017:1" rel="noopener">Shenzhen Mindray Bio-Medical Electronics (300760 CH)</a>, together with the poor financial performance in 2020, perhaps it is a good time to see some concerns of MicroPort.

Microport Scientific (853 HK) is an innovation-driven medical device platform with a diversified product portfolio covering cardiovascular, orthopedics, cardiac rhythm management (“CRM”), endovascular, neurovascular, heart valve, surgical robot and other business. The Company’s high valuation mainly comes from the outlook and embrace of new technologies and new fields. In order to ensure the sustainability of R&amp;D investment, retain talent and maintain growth momentum, subsidiaries were spun-off and then listed one by one when they became mature. Finally, the scope of MicroPort is also expanded, and then the focus can be put on incubating new companies. However, this “unique” pattern of development has also raised questions, especially when compared with Shenzhen Mindray Bio-Medical Electronics (300760 CH), together with the poor financial performance in 2020, perhaps it is a good time to see some concerns of MicroPort.

Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

This Insight summarizes the takeaways from a recent China healthcare industry conference focused on biopharmaceuticals and medical devices, and builds on our Originals Insight <a href="https://www.smartkarma.com/insights/asian-healthcare-coming-of-age" target="_blank" data-smartkarma-citation="insights:45676" rel="noopener">Asian Healthcare - Coming of Age</a>.  Topics addressed include value-based purchasing for drugs and devices; development of commercial health insurance; internet hospitals and online pharmacies; DRGs for hospitals; issues for medical device companies; and amendments to China's patent laws.

This Insight summarizes the takeaways from a recent China healthcare industry conference focused on biopharmaceuticals and medical devices, and builds on our Originals Insight Asian Healthcare - Coming of Age.  Topics addressed include value-based purchasing for drugs and devices; development of commercial health insurance; internet hospitals and online pharmacies; DRGs for hospitals; issues for medical device companies; and amendments to China's patent laws.

China

Specializes in the research, development, manufacture, and sale of artificial joint prostheses & their associated surgical instruments and applications

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AK Medical Holdings Limited (1789 HK)

Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects

This article mainly analyzed MicroPort in terms of the 2021/1H performance, the business, the concerns, the outlook and the advice for investors,...

Xinyao (Criss) Wang

Chunlizhengda Medical Instruments (1858.HK) - The Concerns and the Outlook After Losing the Bidding

This article mainly analyzed Chunlizhengda in terms of the potential impact of losing the bidding on the hip joint prosthesis products, the...

Xinyao (Criss) Wang